The LINC02381/miR-27b-3p/CTNNB1 regulatory axis. (A,B) ESCs were harvested for qRT-PCR after miR-27b-3p expression was increased to quantify the mRNA expression of cyclinD1 (n = 3, P < 0.05) and MMP9 (n = 3, P < 0.01). (C) ESCs were harvested for Western blot analysis after mimic-miR-27b-3p/mimic-NC was added to determine the protein expression of cyclinD1 (n = 3, P < 0.01) and MMP9 (n = 3, P < 0.001). (D) ESCs were harvested for Transwell assays after the expression of miR-27b-3p increased to detect the invasive ability (n = 3, P < 0.001). (E) ESCs were harvested for CCK-8 assays after the expression of miR-27b-3p increased to detect the proliferative ability (n = 3, P < 0.01). (F,G) ESCs were harvested for qRT-PCR after the indicated plasmids were added to quantify the mRNA expression of cyclinD1 (n = 3, P < 0.01; n = 3, P < 0.05, separately) and MMP9 (n = 3, P < 0.05, both). (H) Cells were collected for Western blotting after transfection with the indicated plasmids. LINC02381 knockdown reduced cyclinD1 levels by 37.25% (n = 3, P < 0.05) and MMP9 levels by 52.38% (n = 3, P < 0.01). After the rescue experiment, cyclinD1 increased 1.61-fold (n = 3, P < 0.05) and MMP9 1.52-fold (n = 3, P < 0.05). (I) The indicated plasmids were transfected into ESCs, and cell invasion was evaluated (n = 3, P < 0.05; n = 3, P < 0.001, separately). (J) ESCs were harvested and subjected to CCK-8 assays after transfection (from 24 to 72 h, n = 3, P < 0.05; n = 3, P < 0.01, separately). * P < 0.05, ** P < 0.01, *** P < 0.001.